News
02-14-2011, 07:40 AM
Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that a multi-center Phase 3 study of Lymphoseek® has enrolled clinical subjects to achieve the minimum analysis goal of 196 lymph nodes, the study's primary accrual objective.
More... (http://www.news-medical.net/news/20110214/Neoprobe-achieves-accrual-goal-in-Lymphoseek-Phase-3-study-in-breast-cancermelanoma.aspx)
More... (http://www.news-medical.net/news/20110214/Neoprobe-achieves-accrual-goal-in-Lymphoseek-Phase-3-study-in-breast-cancermelanoma.aspx)